October 08, 2008
Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease
October 07, 2008
New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium
October 06, 2008
New study shows potential benefits of innovative Xolair® anti-IgE therapy in treating children suffering from moderate-to-severe allergic asthma
September 30, 2008
Once-yearly Aclasta® approved in EU to treat osteoporosis in men and to reduce risk of new fractures following hip fracture both in men and postmenopausal women
September 25, 2008
Novartis starts ''squeeze out'' procedure for remaining Speedel shares
September 19, 2008
Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu
September 16, 2008
Latest RAD001 study results show further increase in time without tumor growth in patients with advanced kidney cancer
- New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 versus 1.9 months with placebo
- One quarter of patients in trial remained progression-free beyond ten months of treatment
- RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent® or Nexavar®**, with potential to address unmet medical need
- RAD001 (proposed brand name Afinitor®) under review by regulatory authorities; potential to be first once-daily oral mTOR therapy for advanced kidney cancer
September 15, 2008
Novartis receives FDA priority review for Coartem®, potentially the first artemisinin-based combination treatment (ACT) for malaria in the US
- Coartem achieves high cure rates in studies[1],[2] and since 2001 has helped save an estimated 500,000 lives
- Priority review by FDA underscores urgency of stopping malaria - a key goal of US President's Malaria Initiative
- Working with international community, Novartis has supplied more than 195 million treatments to malaria-endemic countries without profit
September 13, 2008
RAD001 combined with Sandostatin® LAR® and as monotherapy controls growth of rare pancreatic neuroendocrine tumors
- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR
- 77% of patients with pancreatic NET experienced clinical benefit when treated with daily RAD001
- Data show RAD001, an oral mTOR inhibitor, has potential to become new treatment for patients with pancreatic NET who currently have limited options
- Phase III trials underway to confirm impact of combination RAD001 and Sandostatin LAR therapy on survival in pancreatic NET and carcinoid patients
September 10, 2008
New Phase II data show Novartis investigational Meningitis B vaccine may also protect infants six months and older
- Novel vaccine produced protective immune response against broad range of representative meningococcal B strains in more than 95% of infants tested[1]
- Novartis MenB vaccine could fill major unmet need for broadly protective vaccine for children and infants two months and older
- Meningococcal B strains cause 72% of meningococcal disease in Europe and 28% in the US; infants and toddlers are the age group most at risk[2], [3]
